Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury


Creative Commons License

Azılı M. N. , Karakuş E., Şenaylı A., Tiryaki H. T.

Turkish Journal of Pediatric Disease, vol.2019, no.6, pp.475-480, 2019 (Refereed Journals of Other Institutions)

  • Publication Type: Article / Article
  • Volume: 2019 Issue: 6
  • Publication Date: 2019
  • Doi Number: 10.12956/tchd.592543
  • Title of Journal : Turkish Journal of Pediatric Disease
  • Page Numbers: pp.475-480

Abstract

ABSTRACT Objective: Increased levels of Angiotensin II (Ang II) are responsible for the development of hypertension and diabetesinduced nephropathy. In addition, the preventability of renal fibrosis with Ang II blockade is a known entity. Although mast cells are not present in normal kidney, increased mast cell density in the specimens examined for fibrosis has attracted attention and it is thought that fibrotic agents released from these cells and may contribute to the process. Therefore, an experimental study was planned to decrease the ang II levels with captopril, an angiotensin converting enzyme (ACE) inhibitor and to prevent the development of renal scarring due to pyelonephritis using ketotifen, a mast cell stabilizer. Material and Methods: Fifty rats were divided into five equal groups. In Group A, the renal cortex was injected with SF. In Group B, acute pyelonephritis was induced by 107 E. coli injections into the renal cortex. Group C received antibiotic treatment with E. coli injection, Group D received antibiotic and captopril with E. coli injection, Group E. received antibiotic and ketotifen with E. coli injection. In order to represent the chronic process, rats were sacrificed after 6 weeks, and the contralateral kidney was included in pathological examination and statistical evaluation. Results: Inflammatory scores were significantly higher in group B compared to group A (p = 0.001). Captopril or ketotifen treatment were the only factors that reduced scar development (p = 0.007). However, when captopril or ketotifen treatments were compared in preventing scar development, no superiority was found (p> 0.05). Conclusion: We found that captopril and ketotifen has a protective effect in the development of renal fibrosis in a rat model of acute pyelonephritis. We believe that our study may contribute to clinical trials in the prevention of renal scar development.